

## COMPANY OVERVIEW

Cantabio Pharmaceuticals Inc. is a preclinical stage biotechnology company focussing on commercializing novel therapies and the intellectual property generated from our research and development activities for Parkinson's disease (PD), Alzheimer's disease (AD) and other related neurodegenerative diseases.

## RECENT NEWS

**Cantabio Pharmaceuticals to Present Latest Positive In Vivo Results From its DJ-1 Targeting Small Molecule Drug Development Program for Parkinson's Disease at the Milner Therapeutics Symposium at the University of Cambridge, UK**

Oct 1 2018, 9:05 AM EDT

## STOCK OVERVIEW

Symbol	CTBO
Exchange	OTCQB
Market Cap	593.36k
Last Price	\$0.0105
52-Week Range	\$0.0077 - \$0.13

## INVESTOR RELATIONS

Russo Partners LLC  
12 West 27th Street  
4th Floor  
New York, NY 10001  
T: (844) 200-CTBO  
[ir@cantabio.com](mailto:ir@cantabio.com)

## MANAGEMENT TEAM

**Gergely Tóth, Ph.D., M.B.A.**  
Founder, Chief Executive Officer

**Simon Peace, M.Sc., M.B.A., A.C.M.A.**  
Chief Financial Officer

**Thomas Sawyer, Ph.D., M.B.A.**  
Chief Operations Officer

## CANTABIO PHARMACEUTICALS INC.

1250 Oakmead Pkwy  
Sunnyvale, CA 94085  
US

## DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and it's quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.